TITLE

Ulcerative colitis during CTLA-41g therapy in a patient with rheumatoid arthritis

AUTHOR(S)
Amezcua-Guerra, L. M.; Hernández-Martinez, B.; Pineda, C.; Bojalil, R.
PUB. DATE
July 2006
SOURCE
Gut;Jul2006, Vol. 55 Issue 7, p1059
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the case of a 55 year old male with a history of seropositive rheumatoid arthritis refractory to treatment with methotrexate. He was included in the clinical trial of CTLA=4Ig plus MTX clinical trial. Significant clinical and serological responses were achieved during the treatment process. Since CTLA-4Ig has been used to block the interactions between CD80/CD86 on antigen presenting cells and CD28 on T lymphocytes, biological plausibility is possible.
ACCESSION #
21399659

 

Related Articles

  • T-Cell Agents in the Treatment of Rheumatoid Arthritis.  // Bulletin of the NYU Hospital for Joint Diseases;2010, Vol. 68 Issue 3, p162 

    No abstract available.

  • Chelsea Therapeutics Reports on Phase II CH-4051.  // Biotech Business;Jul2012, Vol. 25 Issue 7, p5 

    The article reports on the Phase 2 trial that compares the efficacy and tolerability of the non-metabolized antifolate clinical trial drug, CH-4051, against antimetabolite and antifolate drug methotrexate in patients with rheumatoid arthritis. According to biopharmaceutical company Chelsea...

  • Modulation of APC function and anti-tumor immunity by anti-cancer drugs. Martin, Kea; Schreiner, Jens; Zippelius, Alfred; Barrio, María Marcela; Niedermann, Gabi // Frontiers in Immunology;Sep2015, p1 

    Professional antigen-presenting cells (APCs), such as dendritic cells (DCs), are central to the initiation and regulation of anti-cancer immunity. However, in the immunosuppressive environment within a tumor APCs may antagonize anti-tumor immunity by inducing regulatory T cells (Tregs) or anergy...

  • Methotrexate and oral ulceration. Deeming, G.M.J.; Collingwood, J.; Pemberton, M.N. // British Dental Journal;1/22/2005, Vol. 198 Issue 2, p83 

    Methotrexate is well established in the drug treatment of various neoplastic diseases. More recently it has become increasingly used as a once-weekly, low-dose treatment of disorders such as psoriasis and rheumatoid arthritis. Clinical trials have shown its effectiveness in these conditions and...

  • La célula B en la patogenia de la artritis reumatoide. Díaz-González, José Federico; Amaro, Iván Ferraz // Reumatologia Clinica;jul-ago2007, Vol. 3 Issue 4, p176 

    Classically, B-cells have been considered to play a secondary role in the pathogenesis of rheumatoid arthritis, restricted to the production of auto-antibodies. Nevertheless, the unexpected good clinical response that the systemic depletion of B-cells has demonstrated in a well-controlled...

  • Pulmonary rheumatoid nodules demonstrating features usually associated with rheumatoid synovial membrane. N. Hung; P. Hessian; M. Wilsher // Rheumatology;May2007, Vol. 46 Issue 5, p811 

    Objectives. To describe the unusual immunohistological characteristics of two pulmonary rheumatoid nodules showing ectopic lymphoid follicles and the features normally associated with rheumatoid synovial membrane, and to discuss the implications of this novel observation.Methods. Two...

  • Rituximab NOW Approved for RA. Dunkin, Mary Anne; Ludlam, Kerry // Arthritis Today;May/Jun2006, Vol. 20 Issue 3, p72 

    Reports on the decision of the U.S. Food and Drug Administration to approve the use of rituximab (Rituxan) as a biologic response modifier to be used in combination with methotrexate to reduce the signs and symptoms of rheumatoid arthritis. Mode of administration; Results of the clinical trial.

  • IL-12p70 and IL-18 gene-modified dendritic cells loaded with tumor antigen-derived peptides or recombinant protein effectively stimulate specific Type-1 CD4+ T-cell responses from normal donors and melanoma patients in vitro. Vujanovic, L; Ranieri, E; Gambotto, A; Olson, W C; Kirkwood, J M; Storkus, W J // Cancer Gene Therapy;Aug2006, Vol. 13 Issue 8, p798 

    Although CD4+ Type-1T helper (Th1) cells secreting interferon-γ (IFN-γ) appear to play an essential role in promoting durable antitumor immunity, we have previously shown that patients with cancer exhibit dysfunctional Th1-type responses against epitopes derived from tumor antigens, such...

  • Interferon-β Pretreatment of Conventional and Plasmacytoid Human Dendritic Cells Enhances Their Activation by Influenza Virus. Phipps-Yonas, Hannah; Seto, Jeremy; Sealfon, Stuart C.; Moran, Thomas M.; Fernandez-Sesma, Ana // PLoS Pathogens;Oct2008, Vol. 4 Issue 10, p1 

    Influenza virus produces a protein, NS1, that inhibits infected cells from releasing type I interferon (IFN) and blocks maturation of conventional dendritic cells (DCs). As a result, influenza virus is a poor activator of both mouse and human DCs in vitro. However, in vivo a strong immune...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics